Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 7/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542213 | 0.79 | ALDH1A1 (0.54) | ALDH1A1ALDH1A3EPAS1TSHRTDP1 | |
| SCHEMBL30228794 | 0.78 | L3MBTL1 (0.55) | ALDH1A1ALDH1A3CYP2A6TSHRL3MBTL1 | |
| SCHEMBL6364244 | 0.78 | L3MBTL1 (0.55) | ALDH1A1ALDH1A3CYP2A6TSHRL3MBTL1 | |
| SCHEMBL31727287 | 0.77 | PDIA6 (0.49) | ALDH1A1ALDH1A3CYP2A6TSHRL3MBTL1 | |
| SCHEMBL6542864 | 0.75 | ALDH1A1 (0.54) | ALDH1A1EPAS1TSHRL3MBTL1TDP1 | |
| SCHEMBL9694363 | 0.75 | ALDH1A1 (0.40) | ALDH1A1EPAS1L3MBTL1POLB | |
| SCHEMBL24180006 | 0.74 | ALDH1A1 (0.40) | ALDH1A1ALDH1A3CYP2A6TSHRL3MBTL1 | |
| SCHEMBL2001921 | 0.72 | ALDH1A1 (0.42) | ALDH1A1ALDH1A3CYP2A6TSHRTDP1 | |
| SCHEMBL29417764 | 0.71 | KIF11 (0.51) | ALDH1A1ALDH1A3CYP2A6TSHRHSD17B10 | |
| SCHEMBL3559641 | 0.71 | KIF11 (0.51) | ALDH1A1ALDH1A3CYP2A6TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421061-A4 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INC (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1421061-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | Incyte San Diego Incorporated (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | ALDH1A1 643/4885ALDH1A3 1179/4885EPAS1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.